BIOMAT Database Logo BIOMAT Database Logo

Intensified nutrition as an adjunct to cytotoxic chemotherapy in gynaecological cancer patients. 1982

L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010288 Parenteral Nutrition The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously). Intravenous Feeding,Nutrition, Parenteral,Parenteral Feeding,Feeding, Intravenous,Feeding, Parenteral,Feedings, Intravenous,Feedings, Parenteral,Intravenous Feedings,Parenteral Feedings
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003536 Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed) Cystadenocarcinomas
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004750 Enteral Nutrition Nutritional support given via the alimentary canal or any route connected to the gastrointestinal system (i.e., the enteral route). This includes oral feeding, sip feeding, and tube feeding using nasogastric, gastrostomy, and jejunostomy tubes. Enteral Feeding,Force Feeding,Nutrition, Enteral,Tube Feeding,Gastric Feeding Tubes,Feeding Tube, Gastric,Feeding Tubes, Gastric,Feeding, Enteral,Feeding, Force,Feeding, Tube,Feedings, Force,Force Feedings,Gastric Feeding Tube,Tube, Gastric Feeding,Tubes, Gastric Feeding

Related Publications

L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Lorazepam as an adjunct to antiemetic therapy in patients receiving cytotoxic chemotherapy.
March 1987, Connecticut medicine,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Total parenteral nutrition as an adjunct to chemotherapy of metastatic colorectal cancer.
January 1981, Cancer treatment reports,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy.
February 1983, Australian and New Zealand journal of medicine,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Antiviral chemotherapy as an indicated adjunct to cancer chemotherapy.
January 1975, Cancer chemotherapy reports,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Child nutrition as an adjunct to cancer therapy.
January 1979, JPEN. Journal of parenteral and enteral nutrition,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
February 1975, American journal of surgery,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Nutrition as an adjunct to cancer treatment in the adult.
July 1977, Cancer research,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Hyperpyrexia as an adjunct to chemotherapy.
July 1947, Military surgeon,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Results of chemotherapy as an adjunct to surgery in patients with localized ovarian cancer.
September 1975, Seminars in oncology,
L S Nuutinen, and A Kauppila, and P Ryhänen, and A Niinimäki, and S Kivinen, and M Saarela, and A Pakarinen, and A Hollmén
Chemotherapy as an adjunct to surgery in the treatment of cancer.
February 1963, The Surgical clinics of North America,
Copied contents to your clipboard!